Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.85 USD | -6.99% | -7.83% | -14.90% |
02:12pm | Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $18.8M, vs. Street Est of $21.4M | MT |
05-07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.90% | 435M | |
+4.58% | 109B | |
+11.70% | 105B | |
+0.76% | 22.25B | |
-11.58% | 22.09B | |
-7.56% | 18.68B | |
-38.36% | 17.58B | |
-10.50% | 16.85B | |
+4.74% | 13.76B | |
+36.89% | 12.46B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma : Stifel Adjusts UroGen Pharma's Price Target to $32 from $46, Keeps Buy Rating